yes that would be a Killer Whale ... extremely smart Mammal .. which is not a Fish Lozan
however i could see you getting confused because it looks like one ...
and yes they can eat prey on the beach without paying with bitcoin |
Local delivery
Preclinical studies indicate that intratumoral administration of CTLA-4 blocking antibody in a low dose is as effective
In advanced NSCLC, a relatively low dose of anti-CTLA-4, 25 mg for quavonlimab and 1 mg/kg for ipilimumab, administered every 6 weeks in ...
The use of low-dose combination checkpoint inhibition appears to be a promising approach for improving clinical benefit without significantly increasing adverse ... |
Many multiples -
For those who first were attracted to SCLP by this 'statement', that FAILED to materialise, most have moved-on.
However, a small 'gang' saw the chance to 'clean-up' by overstating the 'riches to come' ...still 'at it' over 12 YEARS on.
Der leader of this 'group' may appear to think,in ALL matters, HE is the biggest fish in the sea
Whereas, REALITY shows = HE is the biggest fish on the beach |
anyway good to see Burble explain to Ruck what commercial business plans look like
and why companies like Scancell structure them for max financial gain from funds available |
I just remember Lindy saying that the vaccines stimulate T Cells but when they go inside a solid tumour can get switched off. The check points protect them and they can do their job.
Re the Neoadjuvant arm of Modi-1 in H&N then they are hopefully close to proving Modi-1`s method of operation.
That coupled with more good results in H&N and Renal in H2 may be enough to convince the big boys to licence at least Modi-1.
In the meantime maybe Genmab starting phase I with SC129 would be great news. |
 its interesting when you look at Rucks posting history ... how the word "dropped" has yet again cropped up ! This time he is asking the Audience, probably hoping for another £199 buy and he feels he can influence. 🤣
So here is today's attempt at negativity
RuckRover
Posts: 5,585
Price: 9.00
No Opinion
Modi1 TrialToday 08:43
When the MODI1 trial was registered on clinical trials, four targets were listed:
Head and Neck
Renal
Ovarian
TN breast cancer
The 2023 year end statement mentions encouraging results in ovarian cancer. More recently, only head and neck and renal cancers are mentioned.
So what happened to the other two targets? Particularly the ovarian patient(s) who had promising results. Have there been official announcements from the company or have they just been quietly dropped?
and here is yesterday
RuckRover - 05 Feb 2025 - 09:01:27 - 17397 of 17491 Scancell - Pot of Gold or POS? - SCLP
Inan,
A nice upbeat post highlighting the scientific theory.
Reminds me of the initial excitement surrounding the Moditope discovery, the fantastic results seen in laboratory mice and the assertion that tumours just "melt away". This, coupled with the claim Moditope would work standalone saw the share price go from 15p to 60p over a three month period.
That was over 12 years ago. The reality has been a little different. In actual human trials, tumours haven't "melted away" and it has been discovered that Moditope will need help from checkpoint inhibitors. One cancer target has been dropped from the trial. These factors has seen the share drop to a 12 month low just over 9p.
So by all means, keep spouting the theory meanwhile the market will assess the facts.
I have every expectation that the "self harm bully boy Club"
Will come out in support of Group think |
from the man that thinks risk dissipates with price !
your really do post some nonsense !
"news follows price"
yet Bitcoin follows Trump 🤣
Best place for you Turkey is "oven ready"
anyway another day for you Turkey, collecting benefit and watching wealth move around
2tyke SMBTS (sad man behind the screen) |
'News desperately needed'
.
Hmmm....at this stage Nigel i'd be careful what you wish for.
News follows price...it doesn't lead. |
If you look at the non- recurrence rate after surgery without Pd-1 its in the 80% bracket, once we have OS data and PFs data from the current trials of Modi1 , it will give an indication on how good Modi1 works on recurrence of distant mets ie. "fresh lesions" which effectively is what neoadjuvant treatment is doing, because in our current trial, Ctl-4 is used only at very early stage ie first few months. Basically Modi1 will be on its own anyway in year 3 or 4, if you then get recurrence, hit it hard with systemic double checkpoint which is at a far higher dose than early adjuvant setting otherwise you are treating the 80% that don't need it with Pd-1 adding toxicity. I strongly believe Modi1 needs the cancer present to activate fully and could be given on day one of diagnose activating while the patient waits surgery.
will check dosage from the trial tomorrow of Pd-1 adjuvant compared to systemic treatment
I don't think Scancell can drop the dosage of ctl-4 its critical to get those T regs turned off once modi1 has control they will not dominate anyway as they are Plastic they may differentiate back to helper t cell rather than suppressor which is why its given short term |
I already said its a $1b min development project |
Well I suppose they are learning all the time as results for Modi arrive. The doublet data will be very interesting.
I would think that whoever licenses Moditope will want to do numerous trials in different settings including Neoadjuvant and maybe earlier in disease , eventually first line.
Not sure about leaving out CPIs. They seem to have great synergy. Lindy did say that less CTLA-4 may be needed so less toxicity.
Then maybe in the future we have that anti-PD-1/CTLA-4 bispecific antibody in trials which apparently has less toxicity. |
I would suggest Moditope in the Neoadjuvant setting, if they trial it, could be very interesting and not bother with the PD-1 why add toxicity
Thoughts Marcus |
The immunotherapy drug pembrolizumab (Keytruda) has rapidly become one of the most widely used cancer treatments. Based on updated results from a large clinical trial, the drug is now part of an important milestone in the treatment of kidney cancer—specifically, clear-cell renal cell carcinoma, the most common form of the disease.
All participants in the trial had earlier-stage kidney cancer and their tumors could be removed with surgery, but they were also at increased risk of their cancer coming back, or recurring. So after undergoing surgery, they were randomly assigned to get pembrolizumab for up to a year or a placebo and routine monitoring.
At 4 years after starting the post-surgical treatment, about 91% of people given pembrolizumab were still alive, compared with 86% of those who received a placebo, according to results published April 17 in the New England Journal of Medicine. Overall, people who received pembrolizumab had a nearly 40% reduced risk of dying during that period.
The findings mark the first time a post-surgical, or adjuvant, treatment for kidney cancer has been shown to help people live longer. |
vaccines were administered after surgery
The vaccines were administered after surgery to remove the tumor and are designed to train the body’s immune system to recognize and eliminate any remaining tumor cells. At the time of data cut-off (median of 34.7 months), all patients remained cancer-free. |
anyway Thanks for the entertainment Ivy |
Ivy arrested for incitement to induce stress in Nigel ...
🙄 |
Nigel now admits to PTSD ...
Ivy you appear to be bringing back bad memories for Nigel
its not me i am posting Blanks ! lol |
Very sad. Been there myself before but without the needless repetitive posting. It's a dangerous place to be. Seek help would be my advice. Mental health is a serious issue. |
Lets hope Nigel has entertained himself tonight
"during blank spaces"
what are you doing Darling ... said Nigels partner
watching Blankety Blank
and i think Lozan has been in a snuff movie .. hoping to catch a glimpse
something about sponge diving
Glued to screen |
what view point Ivy ?
its a pendulum depending which side of the trade your on .. !
what stress ?
if you cannot answer "which one has failed"
then no stress exists ..
and why would somebody under the Stress buy another £1000 today !
some sort of Happy shopper moment ! |
Yep Nigel just the usual inverse relationship between the decrease in the share price which causes him undue stress making him redouble his efforts to post to convince himself he is. right.
Sad really as he could make a contribution if he was willing to accept any other view point which of course he can’t. |
Inan," even Ruck and Ivy moved into the share AFTER moditope news"I was invested in Scancell long BEFORE the Moditope discovery RNS. Where do you get your endless supply of falsehoods and lies? |
you had already developed a Phobia about returning to the UK by then Lozan
and You were very busy with the 7 year broken bottle project
How ever if sponge diving is on your mind ... really at your age |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
